INVESTMENT FORUM - Senegal Is Betting on Forum Invest in Senegal 2025 (Fii 2025) to Accelerate the Inflow of Foreign Capital
In 2024, the country attracted nearly $3 billion in FDI, primarily in energy and infrastructure, according to official data
As the landscape of foreign direct investment (FDI) flows into Africa is being reshaped, Senegal aims to capture a growing share of this capital through the Forum Invest in Senegal 2025 (Fii Senegal 2025) (http://apo-opa.co/3KzxBkp), which opens on Tuesday in Diamniadio.
“Senegal is positioning itself as a crossroads between Africa and the rest of the world, a gateway for attracting capital, technology, and expertise,” explains Bakary Séga Bathily, Director General of APIX, the agency responsible for investment promotion and major infrastructure projects.
With the central theme of ‘connecting opportunities, building the future,’ the event—held under the patronage of His Excellency, President Bassirou Diomaye Diakhar Faye—aims to showcase a portfolio of strategic projects across three key sectors:
Energy: The development of natural gas from Yakaar-Teranga, combined with investments in solar and wind power, aims to position Senegal as a regional energy hub, both as an exporter and a cost-competitive provider of electricity.
Infrastructure: The $1.2 billion Ndayane Port, the Dakar-Bamako transport corridor, and large-scale water projects are designed to strengthen logistical connectivity and secure water supply.
Digital: The development of a sovereign cloud, a national data center, and support for a startup ecosystem in fintech, AI, and cybersecurity aim to diversify the economy beyond traditional sectors.
With growth projected at around 8.4% in 2025, driven by the first gas exports, Dakar aims to strengthen its reputation as a stable and attractive destination for investors.
Beyond the projects themselves, Dakar aims to capitalize on its structural strengths: recognized political stability, a strategic geographic location offering access to 400 million consumers across ECOWAS, and a shifting regulatory framework that includes the new Investment Code, the Startup Act, and a reinforced public-private partnership system.
“Fii Senegal 2025 is more than a forum—it’s a signal to global markets. Senegal seeks to position itself as a key player in Africa’s transformation, guided by transparency, innovation, and sustainability,” emphasizes Bathily.
In 2024, the country attracted nearly $3 billion in FDI, primarily in energy and infrastructure, according to official data. Authorities hope that the 2025 edition of the forum will help turn more announcements into concrete, bankable projects.
Full programme details are available at www.FiiSenegal.sn.
Distributed by APO Group on behalf of APIX Senegal S.A.
Download Image 1: https://apo-opa.co/46ThTbo
Download Image 2: https://apo-opa.co/3VQLuNr
View source version on businesswire.com: https://www.businesswire.com/news/home/20251006277628/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TCG Crossover (“TCGX”) Announces Oversubscribed $1.3B TCGX Fund III6.10.2025 14:00:00 CEST | Press release
TCG Crossover (“TCGX”) today announced the successful closing of its third fund, TCGX Fund III, with $1.3 billion in capital commitments. Fund III attracted support from both current TCGX investors and new institutional investors, foundations, pensions, and endowments. With the close of Fund III, TCGX has now raised more than $3.1 billion in total capital since its founding in 2021. TCGX Fund III exceeded its initial target, underscoring strong global investor demand. The fundraise marks a significant milestone and is an endorsement of the differentiated strategy and TCGX’s fully flexible mandate to invest across both private and public markets. “Exceeding our target for Fund III highlights the deep trust and conviction our investors have placed in our team and approach,” said Dr. Chen Yu, Founder and Managing Partner of TCGX. “We remain steadfast in our mission to back visionary entrepreneurs and companies advancing disruptive medicines to improve patient outcomes.” “We are grateful t
CareDx Announces New IVD Products and IVDR Certification for AlloSeq® Tx and QTYPE®at the 2025 American Society of Histocompatibility & Immunogenetics Annual Meeting6.10.2025 13:05:00 CEST | Press release
Furthers Global Leadership in Donor Organ and Transplant Recipient HLA Typing CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new innovations and products that will be featured at The American Society for Histocompatibility and Immunogenetics (ASHI) 2025 Annual Meeting, held October 6th to 10th in Orlando, Florida. The company also announced that its AlloSeq® Tx and QTYPE® products have received certification for compliance to the In Vitro Diagnostic Regulation (IVDR) in the European Union. “This week at ASHI 2025, we will highlight our continued investment in creating life changing solutions that allow transplant patients to thrive,” said John Hanna, President and Chief Executive Officer. “The new product innovations and regulatory milestone underscore CareDx’s co
Bimiralisib, Topical PI3K/mTOR Inhibitor Shows Up To 92% Clearance Rate And Superior Tolerability In Proof-Of-Concept Actinic Keratosis Study6.10.2025 11:43:00 CEST | Press release
Torqur AG Announced Full Phase 2 Results at EADV Congress 2025 Torqur AG, subsidiary of Swiss Rockets incubator and a clinical-stage company advancing targeted therapies in oncodermatology and oncology, announced the results of the full Phase 2 proof-of-concept study results of topical bimiralisib gel (2%) for the treatment of actinic keratosis (AK) at the European Academy of Dermatology and Venereology (EADV) Congress 2025 in Paris, the largest dermatology conference in Europe. The randomized, multi-center study evaluated topical bimiralisib gel as a field-directed treatment for AK on the face, scalp, and/or back of hands. Results demonstrated substantial efficacy and a favorable safety profile, supporting further clinical development: Efficacy: 92% ofcomplete or near complete response withOlsen grade 1 patients, and overall, 52% of patients in the 2-week period and 71% in the 4-week period achieved an Investigator’s Global Assessment (IGA) score of 0–1 (complete or partial clearance)
Celltrion Presents Positive Real-World Data on Switching from intravenous (IV) to subcutaneous (SC) infliximab at UEG Week 2025 Meet the Expert sessions6.10.2025 11:00:00 CEST | Press release
Switching from intravenous (IV) to subcutaneous (SC) infliximab was shown to be well tolerated, with a low relapse risk for most IBD patients and high treatment persistence1, 2 Celltrion, Inc. today showcased real-world evidence supporting the use of subcutaneous (SC) infliximab, confirming the efficacy and safety of switching to SC infliximab 120mg every two weeks in patients with inflammatory bowel disease (IBD). The real-world evidence was presented at the Meet the Expert (MTE) Sessions at UEG 2025, and included presentations from Professor Nicolas Mathieu, Medical Director of MICI Institut Privé, Cliniques des Cèdres and Associate Professor of Gastroenterology, and Prof Anthony Buisson, Head of IBD Unit at University Hospital Estaing, Clermont Ferrand, France. Professor Nicolas Mathieu presented a real-life study which demonstrated that the switch from IV infliximab to SC infliximab is well tolerated amongst patients. The presentation particularly highlighted the results from the m
Mercans Launches Groundbreaking AI Suite, Redefining Payroll as an Intelligent, Always-On Business Function6.10.2025 10:05:00 CEST | Press release
From real-time payroll to compliance automation, Mercans positions itself as the world’s first truly AI-first payroll company Mercans, a global leader in payroll technology and managed payroll services, today unveiled a sweeping suite of AI-powered innovations that mark a historic shift in the payroll industry. With this launch, Mercans positions itself not as a company with AI features, but as an AI-first organization, embedding intelligence into the very core of payroll, compliance, and client experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006939644/en/ AI-powered payroll. Smarter. Faster. Always compliant (Graphic: AETOSWire) “Payroll has long been seen as a back-office necessity. We are turning it into a front-line strategic advantage. By putting AI at the center of our platform, we’re delivering accuracy, compliance, and insights at a scale and speed never before possible. This is not just about functiona
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom